Alchem Laboratories achieves critical milestones 6th March 2018
Alchem Laboratories Corporation, a contract manufacturing organization located in Alachua, Florida dedicated to excellence in custom synthesis, has announced support of clinical programs and new DOD/NCI contracts for 2018.
DOD contract W81XWH-18-D-0028-awarded in January supports the US Army Medical Research Acquisition Activity with “Non-Personal Services for Experimental Therapeutics Medicinal Chemistry Tasks.” This contract was awarded to procure, synthesize, or purify potential antimalarial drug candidates for the Walter Reed Army Institute of Research. Alchem Laboratories was also awarded two new five-year contracts with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH). Contract HHSN261201700007I “Synthesis of Non-GMP Small Molecules” was awarded September 13, 2017 to synthesize, purify, characterize, and submit to the Drug Synthesis and Chemistry Branch (DSCB), Developmental Therapeutics Program (DTP), Division of Cancer Treatment and Diagnosis (DCTD), NCI, target compounds of high purities and small libraries of analogs of lead compounds. Contract HHSN261201700020C “Manufacture of Bulk Chemicals and Bulk Pharmaceutical Ingredients for Preclinical and Clinical Studies” was awarded July 31, 2017 to support DTP and NCI’s Experimental Therapeutics Program (NExT) to facilitate the transition of novel drug discoveries into clinical trials of new cancer therapeutic agents. These projects have been funded in whole or in part with Federal funds from NCI, NIH, Department of Health and Human Services, under Contract No. HHSN261201700007I (100% Federally funded up to $7,777,665.00) and Contract No. HHSN261201700020C (100% Federally funded up to $2,814,764.00).
“I am proud of the team and progress we have made over the past year. We have achieved critical milestones, with 140 cGMP batches successfully manufactured to support over twenty different government and commercial projects” said Jim Talton, President and CEO. “Twelve of 16 of the active clinical studies currently underway are led by the NCI, which Alchem has been supporting through multiple R&D contracts for over fifteen years. In 2018, we also will continue to work toward rolling scale-up of our GMP clinical manufacturing facility expansion, which is a cornerstone of our long-term strategy to support multiple development programs simultaneously through phase 2/3 clinical studies and commercial production” Talton stated.